DOCSLIB.ORG

Antibiotics in Sepsis: the Basics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibiotics in Sepsis: the Basics author by eLibrary Antibiotics in septic patients in the ER ESCMID © ESCMID eLibrary by author UniversityMiquel Medical Ekkelenkamp Center Utrecht Miquel Ekkelenkamp Antibiotics in septic patients in the ER Disclosure of speaker’s interests (Potential) conflict of interest None author Potentially relevant company relationships in Noneby connection with event 1 • Sponsorship or research funding2 Polyphor AG (through European eLibraryCommision Innovative Medicines Initatiative) • Fee or other (financial) payment3 • Shareholder4 ESCMID5 • Other relationship,© ESCMID i.e. … eLibrary by author 2 Sepsis definitions • “Life-threatening organ dysfunction due to a dysregulated host response to infection.” • Acute increase in 2 or more points in SOFA scoreauthor by • Quick SOFA (for screening): 2 or 3 of: – Hypotension: SBP less than or equal to 100 mmHg – Altered mental status (any GCS less than 15) – Tachypnoea: RR greater thaneLibrary or equal to 22 • Septic shock: – “Sepsis in which underlying circulatory and cellular/metabolic abnormalitiesESCMID are profound enough to substantially increase mortality.”© ESCMID eLibrary by author author Clinical reasoningby in infectious diseases eLibrary Symptoms ESCMID © ESCMID eLibrary by author Disease (Diagnosis) Treatment author Clinical reasoningby in infectious diseases eLibrary Symptoms ESCMID © ESCMID eLibrary by authorPathogen Disease Treatment Clinical reasoning in infectious diseases Pathogen Susceptibility author by Symptoms Disease Treatment eLibrary ESCMID © ESCMID eLibrary by author Antibiotics for sepsis in ER = empiric therapy • Choice similar rationale as other infections: – Treatment usually started before culture results Severity of disease – Less room to “miss” a pathogen author by • R/ should cover the likely pathogens – Also cover likely resistant species • R/ should be “suitable” foreLibrary sepsis – Preferably (rapidly) bactericidal, intravenous • R/ should be supported by clinical evidence of efficacy – Based onESCMID infectious syndrome – Based© onESCMID activity vs pathogen eLibrary by author – If registered for “sepsis” that would also be nice author by WhicheLibrary infections are the main ESCMID © ESCMIDcauses eLibrary of bysepsis? author Main focus bloodstream infection • Community-acquired – Urinary tract – Respiratory tract 60-95% author – Abdominal / biliary tract by • Nosocomial bacteremia: Main foci HAI (all): – 1: Intravascular catheter (40%)eLibrary-Respiratory tract 23.5% – 2: Urinary tract (8%) -Surgical site infections 19.6% -Urinary tract 19% – 3: Surgical site infection (5%) -Catheter-related infections 12.2% – 4: Digestive tract (5%) -Gastro-intestinal 7.6% – 5: PulmonaryESCMID (4%) – 20% unknown © ESCMID eLibraryECDC pointby prevalence author survey hospital- acquired infections 2011-2012 Nethmap 2009, SWAB 2010; EDCD surveillance report 2011-12; Laupland e.a., Clin Microbiol Rev 2014; Søgaard e.a. Clin Microbiol Infect 2015; Cardoso e.a. Acta Med Portug 2013 author by eLibrary Which pathogens are the main ESCMID © ESCMID eLibrarycauses of bysepsis? author Community-acquired bacteremia • 1: Escherichia coli • 2: Streptococcus pneumoniae 60-70% • 3: Staphylococcus aureus • 4: Klebsiella species author by Nosocomial bacteremia eLibrary • 1. Coagulase-negative staphylococci • 2. E. coli Low • 3. S. aureus pathogenicity • 4. EnterococciESCMID • 5. Klebsiella© ESCMID spp eLibrary by author • Some institutions: Candida, P. aeruginosa, Acinetobacter, Enterobacter Refs: see previous slide Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps H. infl Enterobacteriales Non-ferm Acinetobacter author Pseudomonas by eLibrary ESCMID © ESCMID eLibrary by author Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps H. infl Enterobacteriales Non-ferm Penicillin Peni Acinetobacter Augm Amoxicillin / clavulanic acid author Pseudomonas Piptazo Piperacillin / tazobactamby 1st gen: cefazolin Metronida- 2nd gen: cefuroxime zole 3rd gen:eLibrary ceftriaxone 3rd gen: ceftazidime 4th gen: cefepime Meropenem / imipenem Mero/imi ESCMID Clinda © ESCMIDClindamycin eLibrary by authorAztreonam Vancomycin / daptomycin / linezolid Colistin Ciprofloxacin Gentamicin / tobramycin author by eLibrary ESCMID © ESCMID eLibrary by author Are we allowed drugs for sepsis? to use these author by eLibrary FDA labels ESCMID © ESCMID eLibrary by author www.accessdata.fda.gov/scripts/cder/daf / Guidelines, community-acquired sepsis (of unknown origin) • The Netherlands (SWAB-guideline): – Cefuroxime OR ceftriaxone OR amoxi-clav +/- gentamicin / tobramycin – Risk factors for ESBL: add gentamicin or tobramycinauthor – Known ESBL-positive: carbapenem by • Spain (Zaragoza University Hospital): – Ceftriaxone +/- gentamicin – Risk factors for ESBL: carbapenemeLibrary • Surviving sepsis guideline 2016 (no distinction HA-sepsis): – “empiric broad-spectrum therapy to cover all LIKELY pathogens”, if shock “at least ESCMID2 antibiotics of different antibiotic classes” • Sanford© Guide ESCMID (no distinction eLibrary HA-sepsis): by author – Vancomycin + meropenem or imipenem or piperacillin-tazobactam – Alternative: daptomycin + cefepime or piperacillin-tazobactam Basically • Preferably treat with a beta-lactam antibiotic – I.e.: penicillins, cephalosporins, carbapenems or monobactams • Bactericidal author • Usually well-known safety profile by • Usually inexpensive • If necessary: add additional antibiotic – To cover gaps in the desiredeLibrary antibiotic spectrum – Some people say “for synergy” (limited indications) • Always take into account: – Likely focus,ESCMID risk factors for certain pathogens (antibiotic use, comorbidity,© ESCMID etc) eLibrary by author – PRIOR CULTURES (positive and negative) Beta-lactams: 60% of total antibiotic use author by eLibrary Beta-lactams ESCMID © ESCMID eLibrary by author Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps H. infl Enterobacteriales Non-ferm Acinetobacter author Pseudomonas Community-acquiredby sepsis: -Enterobacteriaceae: E. coli, Klebsiella -Streptococci (incl pneumococci) -S. aureus eLibrary ESCMID © ESCMID eLibrary by author Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps H. infl Enterobacteriales Non-ferm Penicillin Peni Acinetobacter Augm Amoxicillin / clavulanic acidauthor Pseudomonas Piptazo Piperacillin / tazobactamby st Metronida- 1 gen: cefazolin zole 2nd gen: cefuroxime 3rd gen:eLibrary ceftriaxone 3rd gen: ceftazidime 4th gen: cefepime Meropenem / imipenem Mero/imi ESCMID Clinda © ESCMIDClindamycin eLibrary by authorAztreonam Vancomycin / daptomycin / linezolid Colistin Ciprofloxacin Gentamicin / tobramycin Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps H. infl Enterobacteriales Non-ferm Acinetobacter author Pseudomonas by S. aureus eLibrary MRSA MSSA ESCMID © ESCMID eLibrary by author Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps H. infl Enterobacteriales Non-ferm Acinetobacter author Pseudomonas by S. aureus eLibrary Enterobacteriales MRSA MSSA ESBL AMP-C Carba-R ESCMID © ESCMID eLibrary by author Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps H. infl Enterobacteriales Non-ferm Acinetobacter author Pseudomonas by S. aureus eLibrary Enterobacteriales MRSA MSSA ESBL AMP-C Carba-R MRSA outpatients:ESCMID ESBL outpatients: <0.1-18© / 100,000ESCMID pt years eLibrary by 2.6%author-40% E.coli Laupland CMR 2014 Talan, 2014 EARS-Net data 2015 Castillo 2015 Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps HI Enterobacteriales NF MRSA ESBL AMP-C CRE author Pseudomonas by eLibrary ESCMID © ESCMID eLibrary by author Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps HI Enterobacteriales NF MRSA ESBL AMP-C CRE author Pseudomonas by Amox/clav A/C AmoxicillineLibrary / clavulanate Cefuroxime Ceftriaxone Mero/imi ESCMIDM/I Meropenem / imipenem © ESCMID eLibraryGentamicin by author / tobramycin / amikacin Colistin Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps HI Enterobacteriales NF MRSA ESBL AMP-C CRE author Pseudomonas by Amox/clav A/C AmoxicillineLibrary / clavulanate Cefuroxime Ceftriaxone Mero/imi ESCMIDM/I Meropenem / imipenem © ESCMID eLibraryGentamicin by author / tobramycin / amikacin Vancomycin / linezolid / daptomycin Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps HI Enterobacteriales NF MRSA ESBL AMP-C CRE Or should we consider an intra-abdominal focus? author Pseudomonas by Metronida- zole Amox/clav A/C AmoxicillineLibrary / clavulanate Cefuroxime Ceftriaxone Mero/imi ESCMIDMeropenem / imipenem © ESCMID eLibraryGentamicin by author / tobramycin / amikacin Clinda Clindamycin Ciprofloxacin Healthcare-associated sepsis • Circulating hospital-specific pathogens – Same micro-organism but more resistant (MRSA,author ESBL, CRE) – Different micro-organism: P. aeruginosa, A. baumannii, Enterobacters, Serratia’s, etc. by • Immunocompromized population – Underlying illness, post-operativeeLibrary status, intravascular access, immunosuppressant medication – Susceptible to wider range of (opportunistic) pathogens: Pseudomonas aeruginosa and other non-fermenters, yeast and fungi ESCMID © ESCMID eLibrary by author Anaerobes Gram-positive Gram-negative Gr- Gr+ CoNS Enterococci S. aureus Streps HI Enterobacteriaceae NF MRSA ESBL AMP-C CRE Acinetobacter author Pseudomonas Amox-clv A-C Amoxicillin-clavulanate Pip-tzb P-T Piperacillin-tazobactam
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION
    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
    [Show full text]
  • Activity of Aztreonam in Combination with Ceftazidime-Avibactam Against
    Diagnostic Microbiology and Infectious Disease 99 (2021) 115227 Contents lists available at ScienceDirect Diagnostic Microbiology and Infectious Disease journal homepage: www.elsevier.com/locate/diagmicrobio Activity of aztreonam in combination with ceftazidime–avibactam against serine- and metallo-β-lactamase–producing ☆ ☆☆ ★ Pseudomonas aeruginosa , , Michelle Lee a, Taylor Abbey a, Mark Biagi b, Eric Wenzler a,⁎ a College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA b College of Pharmacy, University of Illinois at Chicago, Rockford, IL, USA article info abstract Article history: Existing data support the combination of aztreonam and ceftazidime–avibactam against serine-β-lactamase Received 29 June 2020 (SBL)– and metallo-β-lactamase (MBL)–producing Enterobacterales, although there is a paucity of data against Received in revised form 15 September 2020 SBL- and MBL-producing Pseudomonas aeruginosa. In this study, 5 SBL- and MBL-producing P. aeruginosa (1 Accepted 19 September 2020 IMP, 4 VIM) were evaluated against aztreonam and ceftazidime–avibactam alone and in combination via broth Available online xxxx microdilution and time-kill analyses. All 5 isolates were nonsusceptible to aztreonam, aztreonam–avibactam, – – Keywords: and ceftazidime avibactam. Combining aztreonam with ceftazidime avibactam at subinhibitory concentrations Metallo-β-lactamase produced synergy and restored bactericidal activity in 4/5 (80%) isolates tested. These results suggest that the VIM combination of aztreonam and ceftazidime–avibactam may be a viable treatment option against SBL- and IMP MBL-producing P. aeruginosa. Aztreonam © 2020 Elsevier Inc. All rights reserved. Ceftazidime–avibactam Synergy 1. Introduction of SBLs and MBLs harbored by P. aeruginosa are fundamentally different than those in Enterobacterales (Alm et al., 2015; Kazmierczak et al., The rapid global dissemination of Ambler class B metallo-β- 2016; Periasamy et al., 2020; Poirel et al., 2000; Watanabe et al., lactamase (MBL) enzymes along with their increasing diversity across 1991).
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Global Assessment of the Antimicrobial Activity of Polymyxin B Against 54 731 Clinical Isolates of Gram-Negative Bacilli
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01351.x Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004) A. C. Gales1, R. N. Jones2,3 and H. S. Sader1,2 1Division of Infectious Diseases, Universidade Federal de Sa˜o Paulo, Sa˜o Paulo, Brazil, 2JMI Laboratories, North Liberty, IA, USA, and 3Tufts University School of Medicine, Boston, MA, USA ABSTRACT In total, 54 731 Gram-negative bacilli isolated worldwide between 2001 and 2004 from diverse sites of infection were tested for susceptibility to polymyxin B by the broth reference microdilution method, with interpretation of results according to CLSI (formerly NCCLS) guidelines. Polymyxin B showed excellent potency and spectrum against 8705 Pseudomonas aeruginosa and 2621 Acinetobacter spp. isolates (MIC50, £ ⁄ ⁄ 1mg L and MIC90,2mg L for both pathogens). Polymyxin B resistance rates were slightly higher for carbapenem-resistant P. aeruginosa (2.7%) and Acinetobacter spp. (2.8%), or multidrug-resistant (MDR) P. aeruginosa (3.3%) and Acinetobacter spp. (3.2%), when compared with the entire group (1.3% for P. aeruginosa and 2.1% for Acinetobacter spp.). Among P. aeruginosa, polymyxin B resistance rates varied from 2.9% in the Asia-Pacific region to only 1.1% in Europe, Latin America and North America, while polymyxin B resistance rates ranged from 2.7% in Europe to 1.7% in North America and Latin America £ ⁄ % among Acinetobacter spp.
    [Show full text]
  • General Items
    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
    [Show full text]
  • Clinical Review (Cubicin)
    Clinical Review Amol Purandare, MD NDA 021572 Cubicin (Daptomycin for injection) CLINICAL REVIEW Application Type NDA supplement Application Number(s) 21572 Priority or Standard Priority Submit Date(s) June 30, 2016 Received Date(s) June 30, 2016 PDUFA Goal Date March 30, 2017 (Major amendment) Division / Office DAIP/OAP Reviewer Name(s) Amol Purandare, MD Review Completion Date March 23, 2017 Established Name Daptomycin (Proposed) Trade Name Cubicin Therapeutic Class Cyclic Lipopeptide Applicant Cubist Pharmaceuticals Formulation(s) Injection Dosing Regimen 5 mg/kg (12-<18 years), 7 mg/kg (7-11 years), 9 mg/kg (2-6 years), and 10 mg/kg (1-< 2 years) Indication(s) Complicated Skin and Skin Structure Infections 1 Reference ID: 4075320 Clinical Review Amol Purandare, MD NDA 021572 Cubicin (Daptomycin for injection) Intended Population(s) Ages 1 year to <18 years Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT..........................................6 1.1 Recommendation on Regulatory Action ..............................................................6 1.2 Risk Benefit Assessment .....................................................................................6 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ....6 1.4 Recommendations for Postmarket Requirements and Commitments.................7 2 INTRODUCTION AND REGULATORY BACKGROUND .........................................7 2.1 Product Information .............................................................................................7
    [Show full text]
  • Severe Sepsis and Septic Shock Antibiotic Guide
    Stanford Health Issue Date: 05/2017 Stanford Antimicrobial Safety and Sustainability Program Severe Sepsis and Septic Shock Antibiotic Guide Table 1: Antibiotic selection options for healthcare associated and/or immunocompromised patients • Healthcare associated: intravenous therapy, wound care, or intravenous chemotherapy within the prior 30 days, residence in a nursing home or other long-term care facility, hospitalization in an acute care hospital for two or more days within the prior 90 days, attendance at a hospital or hemodialysis clinic within the prior 30 days • Immunocompromised: Receiving chemotherapy, known systemic cancer not in remission, ANC <500, severe cell-mediated immune deficiency Table 2: Antibiotic selection options for community acquired, immunocompetent patients Table 3: Antibiotic selection options for patients with simple sepsis, community acquired, immunocompetent patients requiring hospitalization. Risk Factors for Select Organisms P. aeruginosa MRSA Invasive Candidiasis VRE (and other resistant GNR) Community acquired: • Known colonization with MDROs • Central venous catheter • Liver transplant • Prior IV antibiotics within 90 day • Recent MRSA infection • Broad-spectrum antibiotics • Known colonization • Known colonization with MDROs • Known MRSA colonization • + 1 of the following risk factors: • Prolonged broad antibacterial • Skin & Skin Structure and/or IV access site: ♦ Parenteral nutrition therapy Hospital acquired: ♦ Purulence ♦ Dialysis • Prolonged profound • Prior IV antibiotics within 90 days ♦ Abscess
    [Show full text]
  • Antimicrobial Surgical Prophylaxis
    Antimicrobial Surgical Prophylaxis The antimicrobial surgical prophylaxis protocol establishes evidence-based standards for surgical prophylaxis at The Nebraska Medical Center. The protocol was adapted from the recently published consensus guidelines from the American Society of Health-System Pharmacists (ASHP), Society for Healthcare Epidemiology of America (SHEA), Infectious Disease Society of America (IDSA), and the Surgical Infection Society (SIS) and customized to Nebraska Medicine with the input of the Antimicrobial Stewardship Program in concert with the various surgical groups at the institution. The protocol established here-in will be implemented via standard order sets utilized within One Chart. Routine surgical prophylaxis and current and future surgical order sets are expected to conform to this guidance. Antimicrobial Surgical Prophylaxis Initiation Optimal timing: Within 60 minutes before surgical incision o Exceptions: Fluoroquinolones and vancomycin (within 120 minutes before surgical incision) Successful prophylaxis necessitates that the antimicrobial agent achieve serum and tissue concentrations above the MIC for probable organisms associated with the specific procedure type at the time of incision as well as for the duration of the procedure. Renal Dose Adjustment Guidance The following table can be utilized to determine if adjustments are needed to antimicrobial surgical prophylaxis for both pre-op and post-op dosing. Table 1 Renal Dosage Adjustment Dosing Regimen with Dosing Regimen with CrCl Dosing Regimen with
    [Show full text]
  • In Vitro Susceptibilities of Escherichia Coli and Klebsiella Spp. To
    Jpn. J. Infect. Dis., 60, 227-229, 2007 Short Communication In Vitro Susceptibilities of Escherichia coli and Klebsiella Spp. to Ampicillin-Sulbactam and Amoxicillin-Clavulanic Acid Birgul Kacmaz* and Nedim Sultan1 Department of Central Microbiology and 1Department of Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey (Received January 30, 2007. Accepted April 13, 2007) SUMMARY: Ampicillin-sulbactam (A/S) and amoxicillin-clavulanic acid (AUG) are thought to be equally efficacious clinically against the Enterobacteriaceae family. In this study, the in vitro activities of the A/S and AUG were evaluated and compared against Escherichia coli and Klebsiella spp. Antimicrobial susceptibility tests were performed by standard agar dilution and disc diffusion techniques according to the Clinical and Laboratory Standards Institute (CLSI). During the study period, 973 strains were isolated. Of the 973 bacteria isolated, 823 were E. coli and 150 Klebsiella spp. More organisms were found to be susceptible to AUG than A/S, regardless of the susceptibility testing methodology. The agar dilution results of the isolates that were found to be sensitive or resistant were also compatible with the disc diffusion results. However, some differences were seen in the agar dilution results of some isolates that were found to be intermediately resistant with disc diffusion. In E. coli isolates, 17 of the 76 AUG intermediately resistant isolates (by disc diffusion), and 17 of the 63 A/S intermediately resistant isolates (by disc diffusion) showed different resistant patterns by agar dilution. When the CLSI breakpoint criteria are applied it should be considered that AUG and A/S sensitivity in E. coli and Klebsiella spp.
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]
  • Colistin Combinations Veterinary Medicinal Products Were Identified with Colistin Doses of Below 50,000 IU Per Kg Body Weight
    Annex I List of the names, pharmaceutical forms, strengths of the veterinary medicinal products, animal species, route of administration, and marketing authorisation holders in the Member States Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder Bulgaria Farma vet Ltd. Колитетравит / Oxytetracycline 5.0 g Oral solution Chickens and Oral 40 Otec Paisii str. COLI – TETRAVIT hydrochloride pigs administration Shumen Colistin sulphate 3 500 000 Bulgaria UI Bulgaria COOPHAVET S.A.S. Колисултрикс/ Trimethoprim 3.75 g Oral powder Chickens, Oral administration B.P. 7 Saint Herblon COLISULTRIX Colistin sulphate 50 MIU rabbits, pigs, 44153 ANCENIS calves and Cedex lambs France Croatia Arnika Veterina COLISULTRIX Trimethoprim 3.75 g Oral powder Calves, lambs, Oral d.o.o. Colistin sulphate 50 MIU kids, piglets, Vodovodna 20a poultry and 10000 Zagreb rabbits Croatia Croatia Ceva Santé Animale QUINOCOL Enrofloxacin 100 g Oral solution Chicken, Oral 10 Avenue de la Colistin sulphate 41.67 g turkey Ballastière 33500 Libourne France Cyprus FATRO S.p.A. BACOLAM powder Amoxicillin trihydrate 100 mg Powder for oral Calves, sheep, Administer the Via Emilia, 285 for oral solution for Colistin sulphate 500,000 solution goats, pigs, dose subdivided 40064 Ozzano Emilia calves, sheep, I.U. foals, into two (Bologna) goats, pigs, foals, chickens, administrations Italy chickens, turkeys turkeys each day, (excluding layers) (excluding dissolved in layers) drinking water or in milk. 2/24 Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder Cyprus Vetoquinol Italia ZEMAMIX premix for Amoxicillin trihydrate 11.48 g Premix for Pigs Premix for S.R.L medicated Colistin sulphate 4.00 g medicated medicated Via Piana, 265 feedingstuff for pigs feedingstuff feedingstuff in 47032 Bertinoro insoluble powder, Italy to be administered orally properly mixed in solid feed.
    [Show full text]